CONTE, PAOLA
 Distribuzione geografica
Continente #
NA - Nord America 107
AS - Asia 94
EU - Europa 32
SA - Sud America 8
AF - Africa 1
Totale 242
Nazione #
US - Stati Uniti d'America 103
SG - Singapore 51
HK - Hong Kong 16
CN - Cina 13
VN - Vietnam 7
IE - Irlanda 5
BR - Brasile 4
DE - Germania 4
IN - India 4
IT - Italia 4
RU - Federazione Russa 4
MX - Messico 3
AR - Argentina 2
FR - Francia 2
GB - Regno Unito 2
SE - Svezia 2
AE - Emirati Arabi Uniti 1
AT - Austria 1
AZ - Azerbaigian 1
CA - Canada 1
CZ - Repubblica Ceca 1
EC - Ecuador 1
FI - Finlandia 1
KR - Corea 1
LV - Lettonia 1
NL - Olanda 1
NO - Norvegia 1
PL - Polonia 1
RO - Romania 1
UA - Ucraina 1
VE - Venezuela 1
ZA - Sudafrica 1
Totale 242
Città #
Singapore 24
Hong Kong 16
New York 12
Ashburn 10
Chandler 9
Beijing 5
Dublin 5
Boardman 4
Ho Chi Minh City 4
Princeton 4
Los Angeles 3
Redondo Beach 3
Atlanta 2
Düsseldorf 2
Hanoi 2
Hortolândia 2
Mumbai 2
Nanning 2
Norwalk 2
Phoenix 2
San Diego 2
Udine 2
Woodbridge 2
Amsterdam 1
Baku 1
Brooklyn 1
Bucharest 1
Chennai 1
City of London 1
Comodoro Municipality 1
Cuenca 1
Fort Worth 1
Frankfurt am Main 1
Grand Rapids 1
Guangzhou 1
Haiphong 1
Hefei 1
Helsinki 1
Johannesburg 1
Lanús 1
Manchester 1
Maracaibo 1
Mexico City 1
Milan 1
Newark 1
Nova Friburgo 1
Nuremberg 1
Oklahoma City 1
Old Bridge 1
Olomouc 1
Orem 1
Paris 1
Riga 1
San Juan 1
Santa Clara 1
Seoul 1
Thrissur 1
Trieste 1
Uruapan 1
Vienna 1
Washington 1
Whitewater 1
Wimauma 1
Totale 161
Nome #
Real-world data on treatment outcomes in EGFR-mutant non-small-cell lung cancer patients receiving osimertinib in second or further lines 75
T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study 70
Endocrine‐based treatments in clinically‐relevant subgroups of hormone receptor‐positive/her2‐negative metastatic breast cancer: Systematic review and meta‐analysis 63
Everolimus plus aromatase inhibitors as maintenance therapy after first-line chemotherapy: Final results of the phase III randomised MAIN-A (MAINtenance Afinitor) trial 46
Totale 254
Categoria #
all - tutte 1.573
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.573


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20217 0 0 0 0 0 0 0 0 0 0 4 3
2021/202224 1 9 0 2 0 0 0 1 0 4 3 4
2022/202329 6 0 1 1 4 7 0 0 7 1 1 1
2023/202431 6 1 1 0 7 11 0 0 0 0 1 4
2024/202575 2 5 0 2 6 5 4 5 13 6 8 19
2025/202688 14 23 8 7 35 1 0 0 0 0 0 0
Totale 254